Natera (NASDAQ:NTRA) CFO Sells $5,621,553.52 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 23,948 shares of Natera stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,621,553.52. Following the completion of the sale, the chief financial officer directly owned 99,776 shares of the company’s stock, valued at approximately $23,421,418.24. This represents a 19.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $190.64, for a total value of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The shares were sold at an average price of $191.16, for a total value of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $196.77, for a total transaction of $148,561.35.

Natera Stock Up 0.1%

Shares of NTRA traded up $0.13 during mid-day trading on Thursday, hitting $242.91. The company had a trading volume of 971,052 shares, compared to its average volume of 950,311. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36. The business’s 50-day simple moving average is $233.44 and its 200-day simple moving average is $190.60. The stock has a market cap of $33.60 billion, a PE ratio of -106.07 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period last year, the company posted ($0.26) EPS. On average, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on NTRA. Citigroup initiated coverage on Natera in a research report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target for the company. Evercore ISI lifted their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Wells Fargo & Company boosted their target price on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Barclays increased their target price on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, Guggenheim lifted their price target on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.50.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NTRA. Sound Income Strategies LLC boosted its position in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares during the last quarter. Savvy Advisors Inc. increased its position in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the last quarter. Siemens Fonds Invest GmbH increased its position in shares of Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the last quarter. BOKF NA lifted its stake in shares of Natera by 1.9% in the third quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock worth $601,000 after acquiring an additional 69 shares in the last quarter. Finally, Silvant Capital Management LLC boosted its holdings in Natera by 0.5% in the third quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock valued at $2,171,000 after purchasing an additional 70 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.